Clinical trials: Antiviral Treatment
Chronic HBV Infection
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days treatment with EDP-514.
- Trial name
- NCT04470388
- Testing
- EDP-514
- Where
- 10 sites in Hong Kong, Taiwan
- Volunteers
- 25 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis B, Chronic
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.
- Trial name
- NCT00034359
- Testing
- ACH-126,443, Lamivudine
- Where
- 3 sites in Bulgaria, Federal Republic of Yugoslavia
- Volunteers
- 79 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
- Trial name
- NCT06061081
- Testing
- VH3739937
- Where
- 18 sites in United States, Argentina and 4 more
- Volunteers
- 21 people
- Sponsor
- ViiV Healthcare
Congenital CMV Infection
Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection
Title: Evaluation of Long-term Efficacy of 4-month versus 6-month Course Antiviral Therapy for Neurodevelopmental Impairment Caused by Congenital CMV Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical…
- Trial name
- NCT07450365
- Testing
- Intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily) was administered for a treatment course of 4 months., Patients received a 6-month course of anti-CMV therapy. The treatment regimen consisted of either intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily).
- Volunteers
- 150 people
- Sponsor
- Hu Bofei
Hepatitis B Virus (HBV), Lung Transplant Recipient
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
- Trial name
- CLEAR-HBV (NCT07189377)
- Testing
- Entecavir, HBIG, EVLP UV Light Treatment
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Hepatitis C
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and…
- Trial name
- D-LITE (NCT01309932)
- Testing
- Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV)
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Bristol-Myers Squibb
Influenza
Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
Peramivir is the first intravenous neuraminidase inhibitor (NAI) available for treatment of uncomplicated influenza in adults. Data from placebo-controlled trials in outpatients have shown antiviral efficacy, safety, and…
- Trial name
- NCT02665351
- Testing
- Peramivir
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Chinese University of Hong Kong
Long COVID, Long Covid19
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Trial name
- RECOVER-VITAL (NCT05595369)
- Testing
- Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing
- Where
- 69 sites in United States, Puerto Rico
- Volunteers
- 963 people
- Sponsor
- Kanecia Obie Zimmerman
Hepatitis B
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.
- Trial name
- NCT01765231
- Testing
- Entecavir prophylaxis, Observation arm
- Where
- 13 sites in China
- Volunteers
- 190 people
- Sponsor
- Peking University
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks…
- Trial name
- NCT01701401
- Testing
- LDV/SOF, RBV
- Where
- 88 sites in United States, France and 5 more
- Volunteers
- 870 people
- Sponsor
- Gilead Sciences
Hepatitis C Infection, Thrombocytopenia
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
- Trial name
- NCT01153919
- Testing
- romiplostim, ribavirin, PEG-interferon alfa-2a
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Chronic Hepatitis C, Cirrhosis
Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)
The purpose of this study is to evaluate the effects of sustained virological response in liver and spleen stiffness in patients with HCV compensated advanced chronic liver disease treated with new all oral antiviral drugs in…
- Conditions
- Chronic Hepatitis C, Cirrhosis, Portal Hypertension
- Trial name
- SPLEEN-C (NCT02439567)
- Testing
- Fibroscan: Liver and Spleen elastography
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Chronic Hepatitis B Virus Infection
Antiviral Therapy for Patients With Chronic Hepatitis B Infection
The study aims to demonstrate that antiviral therapy for patients with immune tolerance of CHB. On the basis of the original antiviral therapy of entecavir, further clarify the safety and effectiveness of entecavir combined with…
- Trial name
- NCT05382351
- Testing
- Entecavir, Entecavir combined with Tenofovir Amibufenamide
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Sun Yat-sen University
HIV -1 Infection
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV).
- Trial name
- NCT07392372
- Testing
- BNT351
- Where
- 6 sites in United States, Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Cytomegalovirus Retinitis, HIV Infections
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes
To determine whether alternating oral ganciclovir with intravenous ( IV ) ganciclovir can prevent relapse of Cytomegalovirus ( CMV ) retinitis and improve quality of life in AIDS patients.
- Trial name
- NCT00001062
- Testing
- Ganciclovir
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HCC
Risk of HCC in Cirrhotic Patients Post DAAs Ttt
Direct acting antivirals (DAAs) are a novel and completely oral hepatitis C therapy . DAAs are used in most patients being treated for hepatitis C, including those with decompensated cirrhosis.
- Trial name
- NCT03414554
- Volunteers
- 100 people
- Sponsor
- Assiut University
Coronavirus Disease 2019 (COVID-19)
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support.
- Trial name
- SAC-COVID (NCT04317040)
- Testing
- Efprezimod alfa
- Where
- 10 sites in United States
- Volunteers
- 234 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cervical Cancer, Precancerous Condition
Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00811408
- Testing
- carboplatin, cidofovir, protein expression analysis
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hepatitis C, Chronic
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in…
- Trial name
- NCT01371578
- Testing
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Antiviral Treatment of Chronic Hepatitis B
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
Patients with spontaneous decline of HBV DNA were non-randomly assigned to accept peginterferon alfa-2a or entecavir therapy, or didn't accept any antiviral regiment.
- Trial name
- NCT01892241
- Testing
- Pegasys(Roche), Entecavir
- Volunteers
- 74 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University